Immunological herpes simplex virus antigens and methods for use thereof
AssigneeUniversity of Washington
InventorsDavid M. Koelle, Lawrence Corey
Life of this patent
Estimating the term…
Loading patent…
AssigneeUniversity of Washington
InventorsDavid M. Koelle, Lawrence Corey
Estimating the term…
The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
A pharmaceutical composition comprising an isolated herpes simplex virus (HSV) polypeptide, wherein the polypeptide consists of amino acids 105-126, 125-146, 187-206, 105-190 or 177-220 of UL49 protein, and a pharmaceutically acceptable carrier.
A polynucleotide that encodes a polypeptide consisting essentially of:
A method of enhancing the production of HSV-specific antibodies in a subject comprising administering to the subject an isolated polypeptide that consists of amino acids 105-126, 125-146, 187-206, 105-190 or 177-220 of UL49.
A recombinant non-HSV virus genetically modified to express a polypeptide that consists of amino acids 105-126, 125-146, 187-206, 105-190 or 177-220 of UL49 protein.
A fusion protein comprising an HSV polypeptide fused to a heterologous polypeptide, wherein the HSV polypeptide consists essentially of amino acids 105-126, 125-146, 187-206, 105-190 or 177-220 of UL49.
Dependencies are inferred from the claim text.